



Communication

Acute In Vivo Administration of Compound 21 Stimulates Akt and ERK1/2 Phosphorylation in Mouse Heart and Adipose Tissue

Diego T. Quiroga¹, Jorge A. Narvaéz Pardo¹, María G. Zubiría², Benjamín Barrales¹, Marina C. Muñoz¹, Andrés Giovambattista² and Fernando P. Dominici^{1,*}

¹ Facultad de Farmacia y Bioquímica, Departamento de Química Biológica and IQUIFIB (UBA-CONICET), Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina

² Laboratorio de Neuroendocrinología, Instituto Multidisciplinario de Biología Celular (IMBICE), CICPBA-CONICET-UNLP, La Plata B1906APO, Argentina

* Correspondence: dominici@qb.ffyb.uba.ar

Abstract: The angiotensin II type 2 (AT₂) receptor has a role in promoting insulin sensitivity. However, the mechanisms underlying the AT₂ receptor-induced facilitation of insulin are still not completely understood. Therefore, we investigated whether acute in vivo administration of AT₂ receptor agonist compound 21 (C21) could activate insulin signaling molecules in insulin-target tissues. We report that, in male C57BL/6 mice, an acute (5 min, 0.25 mg/kg; i.v.) injection of C21 induces the phosphorylation of Akt and ERK1/2 at activating residues (Ser473 and Thr202/Tyr204, respectively) in both epididymal white adipose tissue (WAT) and heart tissue. In WAT, the extent of phosphorylation (p) of Akt and ERK1/2 induced by C21 was approximately 65% of the level detected after a bolus injection of a dose of insulin known to induce maximal activation of the insulin receptor (IR). In the heart, C21 stimulated p-Akt to a lesser extent than in WAT and stimulated p-ERK1/2 to similar levels to those attained by insulin administration. C21 did not modify p-IR levels in either tissue. We conclude that in vivo injection of the AT₂ receptor agonist C21 activates Akt and ERK1/2 through a mechanism that does not involve the IR, indicating the participation of these enzymes in AT₂R-mediated signaling.

Keywords: Akt; AT₂ receptor; C21; ERK1/2; signaling



Citation: Quiroga, D.T.; Narvaéz Pardo, J.A.; Zubiría, M.G.; Barrales, B.; Muñoz, M.C.; Giovambattista, A.; Dominici, F.P. Acute In Vivo Administration of Compound 21 Stimulates Akt and ERK1/2 Phosphorylation in Mouse Heart and Adipose Tissue. *Int. J. Mol. Sci.* **2023**, *24*, 16839. <https://doi.org/10.3390/ijms242316839>

Academic Editors: Anastasios Lymperopoulos and Alexis A. Gonzalez

Received: 30 October 2023
Revised: 22 November 2023
Accepted: 25 November 2023
Published: 28 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The renin-angiotensin system modulates insulin action mainly through the actions of its principal peptide angiotensin (Ang) II acting on its two subtypes of receptors, angiotensin type 1 receptor (AT₁R) and angiotensin type 2 receptor (AT₂R), which belong to the G protein-coupled receptor (GPCRs) family [1–5]. Conditions of chronic elevation of Ang II are associated with insulin resistance. This negative effect is mediated by the AT₁R. Inhibition of Ang II action through an AT₁ receptor blockade with specific antagonists or reduction of its production through angiotensin converting enzyme inhibitors results in improvement of glucose homeostasis both in animal models of insulin resistance and/or type 2 diabetes [1–5]. In the last decade, it has been established that the AT₂R exerts a positive effect on insulin sensitivity [6,7]. In general, targeting the AT₂R with pharmacological tools clearly supports a favorable role in glucose metabolism and insulin function. This particularly applies to adipose tissue [6,7]. Pharmacological acute antagonism of the AT₂R with the non-peptide antagonist PD123319 decreased glucose uptake and reduced Akt phosphorylation in rat skeletal muscle [8,9], while chronic blockade of the AT₂R reduced insulin receptor signaling in terms of PI3K/Akt activation in the liver and adipose tissue [10], suggesting a physiological role for the AT₂R. Stimulation of the AT₂R using the established AT₂R agonist C21 has been associated with improved insulin sensitivity in KK-Ay type 2 diabetic mice [11], in rats fed a high-fat/high-fructose diet [12], in healthy

and streptozotocin (STZ)-diabetic rats and mice [13–15], in neonatal STZ-diabetic rats [16], in mice with high-fat diet (HFD)-induced obesity [17,18], in healthy, normal C57BL/6 mice [19] and in female diabetic db/db mice [20]. This physiological role of the AT₂R was also corroborated by a study in AT₂R-knockout (KO) mice, which showed that in these animals displayed higher STZ-induced glycemia coupled with lower pancreatic insulin levels [15]. However, overall, data from AT₂R-KO are controversial and support a beneficial role only in female animals [21,22]. Despite this large amount of evidence for favorable metabolic effects exerted by the AT₂R, the mechanisms by which these effects proceed are not known.

AT₂R-induced intracellular signaling is atypical and different from the traditional modes of signaling displayed by many other GPCRs including the AT₁R [6,7]. Initial AT₂R signaling involves the association of an inhibitory G-protein (Gi) or AT₂R-interacting protein (ATIP) with the AT₂R [7]. These early associations lead to subsequent signaling via phosphatase, kinase, and PPAR γ pathways. There is strong evidence for the involvement of kinases in the intermediate signaling of the AT₂R [6,7]. In human aortic endothelial cells, incubation with C21 has been shown to induce a rapid phosphorylation of Akt and ERK1/2 at activating residues indicating a recruitment of these kinases by the AT₂R [23,24]. There is evidence for the participation of Akt in AT₂R-induced effects including improvement of insulin signaling [19,20], nitric oxide (NO) production [23,25], adipose fat browning [26], proximal tubule albumin endocytosis [27], osmotic cellular resistance [28] and antiproteinuric actions [29]. Participation of ERK1/2 has been reported in various AT₂R-mediated actions such as neuronal differentiation [30], skeletal muscle regeneration [31] and eNOS-mediated vasodilation [32]. However, direct AT₂R-mediated activation of either Akt or ERK1/2 has not been evidenced *in vivo* yet. Thus, the goal of the current work was to determine whether acute intravenous administration of the AT₂R agonist C21 could result in phosphorylation of Akt and ERK1/2 in the metabolic tissues of the mouse *in vivo*. Our results extend the knowledge of the signaling pathways mediated by the AT₂R and indicate that *in vivo* injection of C21 induces the activation of both Akt and ERK in mouse white adipose tissue (WAT) and heart tissue. These findings highlight the importance of these two kinases in AT₂R-mediated signaling.

2. Results

2.1. C21 Induces the Phosphorylation of Akt and ERK1/2 in Mouse White Adipose Tissue (WAT)

For comparison, samples from C21-injected mice were run together with samples of WAT homogenates obtained from insulin (a known recruiter of both Akt and ERK1/2) or vehicle (saline)-injected animals. As compared to baseline values, a bolus injection of insulin known to attain maximal stimulation of the insulin receptor (IR) induced a significant increase in the phosphorylation of the IR at activating Tyr residues (Tyr1158/1162/1163) in WAT (1.6-fold increase; Figure 1A). Accordingly, phospho (p)-Akt-Ser473 levels and p-ERK1/2-Thr202/Tyr204 levels in WAT increased significantly after insulin injection (Figure 1B,C). While acute intravenous injection of C21 did not modify IR phosphorylation in WAT (Figure 1A), acute C21 injection induced a marked and significant increase in both p-Akt and p-ERK1/2 in mouse WAT (Figure 1B,C). The mean level of Akt phosphorylation attained 5 min after C21 administration was approximately 65% of that detected after insulin injection (Figure 1B), while the level of ERK1/2 phosphorylation was comparable to that induced by *in vivo* insulin administration (Figure 1C). The protein abundance of IR, Akt and ERK1/2 in WAT was not modified after either treatment with saline, insulin or C21 (Figure 1A–C).




Figure 1. C21 stimulates the phosphorylation of Akt and ERK1/2 in mouse adipose tissue. The phosphorylation level and total abundance of the insulin receptor (IR) (A), Akt (B) and ERK1/2 (C) were evaluated in epididymal adipose tissue homogenates by Western blot. Western blot membranes were stained with Coomassie Blue for loading control. The phosphorylation-to-protein ratio was calculated for each sample. Data are expressed as mean \pm SEM ($n = 6$ for all groups). A representative image is presented. All analyses were carried out using GraphPad Prism 8.0.

2.2. C21 Induces the Phosphorylation of Akt and ERK1/2 in Mouse Heart

As compared to baseline values, *in vivo* intravenous injection of insulin induced an approximate 3.5-fold increase in IR phosphorylation at activating residues Tyr1158/1162/1163 (Figure 2A) while, as expected, C21 did not modify IR phosphorylation in mouse heart tissue (Figure 2A).




Figure 2. C21 stimulates the phosphorylation of Akt and ERK1/2 in mouse heart. The phosphorylation level and total abundance of the insulin receptor (IR) (A), Akt (B) and ERK1/2 (C) were evaluated in heart homogenates by Western blot. Western blot membranes were stained with Coomassie Blue for loading control. The phosphorylation-to-protein ratio was calculated for each sample. Data are expressed as mean \pm SEM ($n = 6$ for all groups). All analyses were carried out using GraphPad Prism 8.0.

Similarly to what was detected for WAT, *in vivo* C21 injection stimulated the phosphorylation levels of Akt at Ser473 by approximately 2.5–3-fold in heart tissue (Figure 2B). However, this stimulation was only a fraction of that attained after insulin administration using the same protocol. When heart homogenates were probed with an anti p-ERK1/2-Thr202/Tyr204 antibody, an approximate 1.8-fold increase over baseline values was detected for ERK1/2 phosphorylation in heart tissue after *in vivo* C21 injection (Figure 2C). The mean level of Akt phosphorylation attained 5 min after C21 administration was approximately 25% of that detected after insulin injection (Figure 2B), while the level of ERK1/2 phosphorylation was comparable to that induced by *in vivo* insulin administration (Figure 2C). The protein abundance of IR, Akt and ERK1/2 in heart tissue was not modified after either treatment with saline, insulin or C21 (Figure 2A–C).

3. Discussion

The AT₂R is one of the main receptors within the protective arm of the RAS, others being MAS and insulin-regulated aminopeptidase [6,7]. Compared to other GPCRs of therapeutic significance, the development of drugs targeting the AT₂R for therapeutic use of its protective and regenerative properties has been slow [6]. The difficulty in determining robust parameters for the detection of AT₂R effects is likely a major reason for this delay. Since the signaling pathways afford AT₂R the ability to exert protective actions in multiple disease states—sometimes in direct opposition to deleterious AT₁R-mediated effects—the investigation of these pathways is a topic of importance. Recent reports have reinforced the notion that *in vivo* stimulation of the AT₂R with C21 leads to major beneficial actions, including reduction of inflammation [33], attenuation of cardiac fibrosis [34], antagonism of the thromboxane receptor [35], enhancement of insulin sensitivity and amelioration of type-2 diabetes complications [6,19,20].

Intracellular signaling induced by the AT₂R is atypical and remarkably it does not share a resemblance with traditional modes of signaling displayed by many other GPCRs, including the AT₁R [6,35,36]. There is evidence that AT₂R signaling events include the participation of phosphatases, kinases and PPAR pathways. In addition, accumulated evidence indicates that there is a large variety of AT₂R-stimulated signal transduction pathways, with evidence for both G-protein-dependent and independent mechanisms, a common pattern for GPCRs [6,37,38]. Activation of protein phosphatases is a central intermediate step in AT₂R signaling, regardless of whether the upstream signaling involves G-proteins or not [6,7,39].

While the signaling pathways employed by the AT₂R have been the focus of intense research efforts, the role of downstream kinase and phosphatase pathways on AT₂R-mediated actions requires further investigation. Our results are indicative of the participation of both Akt and ERK1/2 in AT₂R signaling in both white adipose tissue and heart tissue—tissues known to express the AT₂R [6,7]. These results are in good agreement with previous reports indicating that stimulation of the AT₂R using C21 induces Akt phosphorylation in human aortic endothelial cells (HAECs), an event that was linked to NO production [23]. More recently, the phosphorylation status of HAECs after stimulation with C21 was determined utilizing time-resolved quantitative phosphoproteomics, showing that AT₂R stimulation induces the phosphorylation and dephosphorylation of 172 proteins, of which, a large proportion are involved in antiproliferation and apoptosis [24]. Computer-based kinase prediction found that both Akt and ERK1/2 take part in AT₂R-signaling. Participation of these kinases in AT₂R-mediated signaling in HAECs was confirmed by Western Blotting [39]. Our current findings are in excellent correlation with this study and indicate that these events also take place *in vivo* and thus they could be of physiological relevance. At present, it is, however, not known how the connection between the AT₂R and these downstream kinases proceeds. Unlike most other GPCRs, the AT₂R does not associate with β -arrestin [40]. Since physical interaction of the AT₂R with other receptors such as AT₁R, B₂R and Mas and with several other binding proteins has been established [41], we hypothesize that these interactions could be relevant for current findings.

Of note, current results support the participation of the kinases Akt and ERK1/2 that has been reported in several AT₂R-mediated actions such as improvement of insulin signaling [19,20], NO synthesis [23,24], adipose fat browning [25], proximal tubule albumin endocytosis [26], osmotic cellular resistance [27], antiproteinuric actions [28] and anti-fibrotic effects [37], for Akt, and neuronal differentiation [29] skeletal muscle regeneration [30], endothelial NO synthase-mediated vasodilation [31] and mitogen-activated protein kinase phosphatase activation [39], in the case of ERK1/2. Our previous reports involving pharmacological agonism or blockade of the AT₂R and mice with global deletion of the AT₂R [10,19,20,22] suggested that the presence of the AT₂R in adipose tissue is critical to the role of this receptor in the control of insulin action and glucose homeostasis. Considering current findings, it is hypothesized that the kinases Akt and ERK1/2, known

to participate in the control of metabolism, could have a role in AT₂R-mediated metabolic actions in this tissue.

When analyzing the strengths of the study, we considered the following aspects: (a) results contribute to expanding the knowledge of AT₂R-mediated signaling pathways, strongly supporting the participation of kinases aside from phosphatases; (b) the detection of Akt and ERK1/2 phosphorylation in mouse tissues through the use of phospho-specific antibodies make the results unequivocal; and (c) reported results are ascribed to AT₂R agonism since C21 is a compound with proven specificity towards this receptor. Noteworthy, it must be mentioned that this study has several limitations. Namely: (a) the utilization of a single species, a single gender and a single dose of C21 at a one-time point is not enough to fully characterize the selectivity and efficacy of the *in vivo* activation of the analyzed kinases [42]; (b) analysis of Akt and ERK1/2 phosphorylation after co-infusion of C21 with an AT₂R antagonist would be important to further corroborate that activation of the studied kinases is AT₂R-mediated; (c) it would be of value to demonstrate that the actions originated by stimulation with C21 are not present in cells in which the AT₂R is either absent or silenced.

In conclusion, current findings provide new information that contributes to the knowledge of AT₂R-signaling, by the identification of functional AT₂Rs in mouse adipose tissue and heart tissue and the demonstration of Akt and ERK1/2 phosphorylation upon *in vivo* activation of AT₂R in these tissues.

4. Materials and Methods

4.1. Experimental Animals

All experiments were approved by the Institutional Animal Care and Use Committee of the School of Pharmacy and Biochemistry of the University of Buenos Aires. Adult (3–4 months old) C57BL/6 male mice were used. Animals were housed 3–5 per cage in a room with controlled light (12 h light: 12 h darkness cycle) and temperature (22 ± 2 °C). Mice had free access to a nutritionally balanced diet and tap water.

4.2. *In Vivo* Administration of C21 and Tissue Collection

Compound 21 was obtained through Vicore Pharma AB (Göteborg, Sweden). The dose of C21 was calculated based on previous studies aimed at exploring vasodilation or insulin enhancement effects derived from *in vivo* AT₂R stimulation [43,44]. With a molecular weight of 475.63 g/mol and the assumption of a blood volume of 1.8 mL in a 20-g mouse [45], the maximal blood concentration of C21 attained immediately after injection would be in the range of 8–10 μ M, assuming that no degradation occurred during the timeframe of the experiment. At this concentration, C21 has been shown to evoke vasodilation and to facilitate insulin delivery to tissues [43,44]. The duration of the treatment was selected from previously published studies [23,24].

4.3. Western Blot

Western blotting procedures used in this study have been reported previously [19,20]. Information on all antibodies used is presented in Table S1. Adipose tissue and heart extracts were denatured, resolved by SDS-PAGE, transferred into PVDF membranes (Millipore Immobilon-FL; EMD Millipore, Billerica, MA, USA) and finally probed with specific antibodies: anti-phospho-Tyr 1158/1162/1163 insulin receptor β subunit (Millipore, Burlington, MA, USA), IR β subunit (GeneTex, Irvine, CA, USA), Akt, phospho-Ser 473 Akt, ERK1/2 or phospho-Thr202/Tyr204 ERK1/2 (Cell Signaling, Danvers, MA, USA). Immunoreactive bands were detected by chemiluminescence (Pierce™ ECL Plus Western Blotting Substrate, Thermo Fisher Scientific, Waltham, MA, USA). Protein loading control was performed by relativizing protein content to Coomassie Blue staining of PVDF membranes after blotting experiments as previously described [46]. The level of each protein evaluated was normalized to the area obtained from control samples to avoid sources of variation. Phosphorylation values were then related to calculated protein values for each

protein analyzed (IR, Akt and ERK1/2). To assess the error of the control group, each individual control value was divided by average intensity obtained for the control group (saline-injected mice). The units shown in bar graphs were obtained by considering the average value of intensity of each specific band in the control group as $100\% \pm \text{S.E.M.}$. The molecular weight of proteins was estimated using pre-stained protein markers (Bio-Rad, Hercules, CA, USA).

4.4. Statistical Analysis

Data are presented as mean \pm SEM. Comparisons were performed via one-way ANOVA with the post-hoc Tukey method for multiple groups using Prism software 8.0 (GraphPad, San Diego, CA, USA). Differences were considered statistically significant at $p < 0.05$.

Supplementary Materials: The supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms242316839/s1>.

Author Contributions: Conceptualization, F.P.D.; methodology, F.P.D., M.G.Z., J.A.N.P., B.B. and M.C.M.; formal analysis, F.P.D.; resources, F.P.D.; data curation, D.T.Q. and J.A.N.P.; writing—original draft preparation, F.P.D.; writing—review and editing, F.P.D., M.G.Z. and A.G.; funding acquisition, F.P.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the University of Buenos Aires, grant number 20020170100116BA and the AGENCIA NACIONAL DE PROMOCIÓN CIENTÍFICA Y TECNOLÓGICA (ANPCyT), grant number PICT-2019-0051 to F.P.D.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee “CICUAL” of the School of Pharmacy and Biochemistry, University of Buenos Aires (Res. 1368/2018, date of approval 17 April 2018).

Data Availability Statement: Data is contained within the article and Supplementary Material.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| | |
|-------------------|--|
| Ang | Angiotensin |
| AT ₁ R | Angiotensin II receptor type 1 |
| AT ₂ R | Angiotensin II receptor type 2 |
| ATIP | AT ₂ R-interacting protein |
| C21 | Compound 21 |
| GPCR | G protein-coupled receptor |
| IR | Insulin receptor |
| KO | Knockout |
| NO | Nitric oxide |
| PPAR | Peroxisome proliferator-activated receptor |
| NO | Nitric oxide |
| STZ | Streptozotocin |
| WAT | White adipose tissue |

References

1. Folli, F.; Kahn, C.R.; Hansen, H.; Bouchie, J.L.; Feene, E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. *J. Clin. Investig.* **1997**, *100*, 2158–2169. [[CrossRef](#)] [[PubMed](#)]
2. Henriksen, E.J. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2007**, *293*, R974–R980. [[CrossRef](#)] [[PubMed](#)]
3. Shiuchi, T.; Iwai, M.; Li, H.S.; Wu, L.; Min, L.J.; Li, J.M.; Okumura, M.; Cui, T.X.; Horiuchi, M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. *Hypertension* **2004**, *43*, 1003–1010. [[CrossRef](#)] [[PubMed](#)]
4. Favre, G.A.; Esnault, V.L.; Van Obberghen, E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. *Am. J. Physiol. Endocrinol. Metab.* **2015**, *308*, E435–E449. [[CrossRef](#)] [[PubMed](#)]

5. Muñoz, M.C.; Giani, J.F.; Dominici, F.P.; Turyn, D.; Toblli, J.E. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. *J. Hypertens.* **2009**, *27*, 2409–2420. [[CrossRef](#)] [[PubMed](#)]
6. Steckelings, U.M.; Widdop, R.E.; Sturrock, E.D.; Lubbe, L.; Hussain, T.; Kaschina, E.; Unger, T.; Hallberg, A.; Carey, R.M.; Sumners, C. The angiotensin AT₂ receptor: From a binding site to a novel therapeutic target. *Pharmacol. Rev.* **2022**, *74*, 1051–1135. [[CrossRef](#)]
7. Fatima, N.; Patel, S.N.; Hussain, T. Angiotensin II type 2 receptor: A target for protection against hypertension, metabolic dysfunction, and organ remodeling. *Hypertension* **2021**, *77*, 1845–1856. [[CrossRef](#)]
8. Chai, W.; Wang, W.; Dong, Z.; Cao, W.; Liu, Z. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. *Diabetes* **2011**, *60*, 2939–2946. [[CrossRef](#)]
9. Chai, W.; Wang, W.; Liu, J.; Barrett, E.J.; Carey, R.M.; Cao, W.; Liu, Z. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. *Hypertension* **2010**, *55*, 523–530. [[CrossRef](#)]
10. Muñoz, M.C.; Burghi, V.; Miquet, J.G.; Cervino, I.A.; Quiroga, D.T.; Mazziotta, L.; Dominici, F.P. Chronic blockade of the AT₂ receptor with PD123319 impairs insulin signaling in C57BL/6 mice. *Peptides* **2017**, *88*, 37–45. [[CrossRef](#)]
11. Ohshima, K.; Mogi, M.; Jing, F.; Iwanami, J.; Tsukuda, K.; Min, L.-J.; Ogimoto, A.; Dahlöf, B.; Steckelings, U.M.; Unger, T.; et al. Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPAR γ activation. *PLoS ONE* **2012**, *7*, e483. [[CrossRef](#)] [[PubMed](#)]
12. Shum, M.; Pinard, S.; Guimond, M.-O.; Labbé, S.M.; Roberge, C.; Baillargeon, J.-P.; Langlois, M.F.; Alterman, M.; Wallinder, C.; Hallberg, A.; et al. Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high fat/high-fructose diet-induced insulin resistance in rats. *Am. J. Physiol. Endocrinol. Metab.* **2013**, *304*, E197–E210. [[CrossRef](#)] [[PubMed](#)]
13. Shao, C.; Yu, L.; Gao, L. Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. *Endocrinology* **2014**, *155*, 793–804. [[CrossRef](#)] [[PubMed](#)]
14. Shao, C.; Zucker, I.H.; Gao, L. Angiotensin type 2 receptor in pancreatic islets of adult rats: A novel insulinotropic mediator. *Am. J. Physiol. Endocrinol. Metab.* **2013**, *305*, E1281–E1291. [[CrossRef](#)]
15. Koullis, C.; Chow, B.S.M.; McKelvey, M.; Steckelings, U.M.; Unger, T.; Thallas-Bonke, V.; Thomas, M.C.; Cooper, M.E.; Jandeleit-Dahm, K.A.; Allen, T.J. AT₂R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. *Hypertension* **2015**, *65*, 1073–1081. [[CrossRef](#)] [[PubMed](#)]
16. Wang, L.; Wang, Y.; Li, X.Y.; Leung, P.S. Angiotensin II type 2 receptor activation with Compound 21 augments islet function and regeneration in streptozotocin-induced neonatal rats and human pancreatic progenitor cells. *Pancreas* **2017**, *46*, 395–404. [[CrossRef](#)]
17. Nag, S.; Khan, M.A.; Samuel, P.; Ali, Q.; Hussain, T. Chronic angiotensin AT₂R activation prevents high-fat diet-induced adiposity and obesity in female mice independent of estrogen. *Metabolism* **2015**, *64*, 814–825. [[CrossRef](#)]
18. Nag, S.; Patel, S.; Mani, S.; Hussain, T. Role of angiotensin type 2 receptor in improving lipid metabolism and preventing adiposity. *Mol. Cell. Biochem.* **2019**, *461*, 195–204. [[CrossRef](#)]
19. Quiroga, D.T.; Muñoz, M.C.; Gil, C.; Pfeifer, M.; Toblli, J.E.; Steckelings, U.M.; Giani, J.F.; Dominici, F.P. Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice. *Physiol. Rep.* **2018**, *6*, e13824. [[CrossRef](#)]
20. Dominici, F.P.; Veiras, L.C.; Shen, J.Z.Y.; Bernstein, E.A.; Quiroga, D.T.; Steckelings, U.M.; Bernstein, K.E.; Giani, J.F. Activation of AT₂ receptors prevents diabetic complications in female db/db mice by NO-mediated mechanisms. *Br. J. Pharmacol.* **2020**, *177*, 4766–4781. [[CrossRef](#)]
21. Samuel, P.; Khan, M.A.; Nag, S.; Inagami, T.; Hussain, T. Angiotensin AT₂ receptor contributes towards gender bias in weight gain. *PLoS ONE* **2013**, *8*, e48425. [[CrossRef](#)] [[PubMed](#)]
22. Quiroga, D.T.; Miquet, J.G.; Gonzalez, L.; Sotelo, A.I.; Muñoz, M.C.; Geraldes, P.M.; Giani, J.F.; Dominici, F.P. Mice lacking angiotensin type 2 receptor exhibit a sex specific attenuation of insulin sensitivity. *Mol. Cell. Endocrinol.* **2019**, *498*, 110587. [[CrossRef](#)] [[PubMed](#)]
23. Peluso, A.A.; Bertelsen, J.B.; Andersen, K.; Mortensen, T.P.; Hansen, P.B.; Sumners, C.; Bader, M.; Santos, R.A.; Steckelings, U.M. Identification of protein phosphatase involvement in the AT₂ receptor-induced activation of endothelial nitric oxide synthase. *Clin. Sci.* **2018**, *132*, 777–790. [[CrossRef](#)] [[PubMed](#)]
24. Peluso, A.A.; Kempf, S.J.; Verano-Braga, T.; Rodrigues-Ribeiro, L.; Johansen, L.E.; Hansen, M.R.; Kitlen, G.; Haugaard, A.H.; Sumners, C.; Ditzel, H.J.; et al. Quantitative phosphoproteomics of the angiotensin AT₂-Receptor signaling network identifies HDAC1 (histone-deacetylase-1) and p53 as mediators of antiproliferation and apoptosis. *Hypertension* **2022**, *79*, 2530–2541. [[CrossRef](#)] [[PubMed](#)]
25. Hiromi, H.; Katsutoshi, Y.; Masaoki, T.; Hiroshi, O. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. *Hypertension* **2005**, *45*, 967–973.
26. Than, A.; Xu, S.; Li, R.; Leow, M.K.-S.; Sun, L.; Chen, P. Angiotensin type 2 receptor activation promotes browning of white adipose tissue and brown adipogenesis. *Signal Transduct. Target Ther.* **2017**, *2*, 17022. [[CrossRef](#)] [[PubMed](#)]
27. Caruso-Neves, C.; Kwon, S.-H.; Guggino, W.B. Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT₂ receptor-mediated protein kinase B activation. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 17513–17518. [[CrossRef](#)]

28. Guimarães-Nobre, C.C.; Mendonça-Reis, E.; Passinho-da-Costa, L.; Miranda-Alves, L.; Berto-Junior, H.C. Signaling pathway in the osmotic resistance induced by angiotensin II AT₂ receptor activation in human erythrocytes. *Rep. Biochem. Mol. Biol.* **2021**, *10*, 314–326. [[CrossRef](#)]
29. Kulkarni, K.; Patel, S.; Ali, R.; Hussain, P. Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats. *Sci. Rep.* **2023**, *13*, 4277. [[CrossRef](#)]
30. Stroth, U.; Blume, A.; Mielke, K.; Unger, T. Angiotensin AT₂ receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. *Brain Res. Mol. Brain Res.* **2000**, *78*, 175–180. [[CrossRef](#)]
31. Yoshida, T.; Huq, T.S.; Delafontaine, P. Angiotensin Type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration. *J. Biol. Chem.* **2014**, *289*, 26239–26248. [[CrossRef](#)] [[PubMed](#)]
32. Hagihara, G.N.; Lobato, N.S.; Filgueira, F.P.; Akamine, E.H.; Aragão, D.S.; Casarini, D.E.; Carvalho, M.H.C.; Fortes, Z.B. Upregulation of ERK1/2-eNOS via AT₂ receptors decreases the contractile response to angiotensin II in resistance mesenteric arteries from obese rats. *PLoS ONE* **2014**, *9*, e106029. [[CrossRef](#)] [[PubMed](#)]
33. Sampson, A.K.; Irvine, J.C.; Shihata, W.A.; Dragoljevic, D.; Lumsden, N.; Huet, O.; Barnes, T.; Unger, T.; Steckelings, U.M.; Jennings, G.L.; et al. Compound 21, a selective agonist of angiotensin AT₂ receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo. *Br. J. Pharmacol.* **2016**, *173*, 729–740. [[CrossRef](#)] [[PubMed](#)]
34. Castoldi, G.; Carletti, R.; Ippolito, S.; Stella, A.; Zerbini, G.; Pelucchi, S.; Zatti, G.; di Gioia, C.R.T. Angiotensin type 2 and Mas receptor activation prevents myocardial fibrosis and hypertrophy through the reduction of inflammatory cell infiltration and local sympathetic activity in angiotensin II-dependent hypertension. *Int. J. Mol. Sci.* **2021**, *22*, 13678. [[CrossRef](#)] [[PubMed](#)]
35. Fredgart, M.H.; Leurgans, T.M.; Stenelo, M.; Nybo, M.; Bloksgaard, M.; Lindblad, L.; De Mey, J.G.R.; Steckelings, U.M. The angiotensin AT₂-receptor agonist compound 21 is an antagonist for the thromboxane TP-receptor—Implications for preclinical studies and future clinical use. *Peptides* **2023**, *164*, 170990. [[CrossRef](#)] [[PubMed](#)]
36. Forrester, S.J.; Booz, G.W.; Sigmund, C.D.; Coffman, T.M.; Kawai, T.; Rizzo, V.; Scalia, R.; Eguchi, S. Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology. *Physiol. Rev.* **2018**, *98*, 1627–1738. [[CrossRef](#)] [[PubMed](#)]
37. Sumners, C.; Peluso, A.A.; Haugaard, A.H.; Bertelsen, J.B.; Steckelings, U.M. Anti-fibrotic mechanisms of angiotensin AT₂-receptor stimulation. *Acta Physiol.* **2019**, *227*, e13280. [[CrossRef](#)]
38. Hilger, D.; Masureel, M.; Kobilka, B.K. Structure and dynamics of GPCR signaling complexes. *Nat. Struct. Mol. Biol.* **2018**, *25*, 4–12. [[CrossRef](#)]
39. Shchepinova, M.M.; Hanyaloglu, A.C.; Frost, G.S.; Tate, E.W. Chemical biology of non-canonical G protein-coupled receptor signaling: Toward advanced therapeutics. *Curr. Opin. Chem. Biol.* **2020**, *56*, 98–110. [[CrossRef](#)]
40. Turu, G.; Szidonya, L.; Gáborik, Z.; Buday, L.; Spät, A.; Clark, A.J.L.; Hunyady, L. Differential beta-arrestin binding of AT₁ and AT₂ angiotensin receptors. *FEBS Lett.* **2006**, *580*, 41–45. [[CrossRef](#)]
41. Colin, M.; Delaitre, D.; Foulquier, S.; Dupuis, F. The AT₁ / AT₂ receptor equilibrium is a cornerstone of the regulation of the renin angiotensin system beyond the cardiovascular system. *Molecules* **2023**, *28*, 5481. [[CrossRef](#)] [[PubMed](#)]
42. Goutaudier, R.; Coizet, V.; Carcenac, C.; Carnicella, S. Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats. *PLoS ONE* **2020**, *15*, e0238156. [[CrossRef](#)] [[PubMed](#)]
43. Bosnyak, S.; Welungoda, I.K.; Hallberg, A.; Alterman, M.; Widdop, R.E.; Jones, E.S. Stimulation of angiotensin AT₂ receptors by the nonpeptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. *Br. J. Pharmacol.* **2010**, *159*, 709–716. [[CrossRef](#)] [[PubMed](#)]
44. Yan, F.; Yuan, Z.; Wang, N.; Carey, R.M.; Aylor, K.W.; Chen, L.; Zhou, X.; Liu, Z. Direct activation of angiotensin II type 2 receptors enhances muscle microvascular perfusion, oxygenation, and insulin delivery in male rats. *Endocrinology* **2018**, *159*, 685–695. [[CrossRef](#)]
45. Riches, A.C.; Sharp, J.G.; Brynmor Thomas, D.; Vaughan Smith, S. Blood volume determination in the mouse. *J. Physiol.* **1973**, *228*, 279–284. [[CrossRef](#)]
46. Welinder, C.; Ekblad, L. Coomassie staining as loading control in Western blot analysis. *J. Proteome Res.* **2011**, *10*, 1416–1419. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.